Staphylococcus aureus bacteraemia and endocarditis – epidemiology and outcome: a review
H Asgeirsson, A Thalme, O Weiland - Infectious Diseases, 2018 - Taylor & Francis
Purpose: To review the epidemiology of Staphylococcus aureus bacteraemia (SAB) and
endocarditis (SAE), and discuss the short- and long-term outcome. Materials and methods: A …
endocarditis (SAE), and discuss the short- and long-term outcome. Materials and methods: A …
[HTML][HTML] Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a …
…, M Akber, D Valentini, AC Norlin, A Thalme… - …, 2021 - thelancet.com
Background Patients with immunocompromised disorders have mainly been excluded from
clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial …
clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial …
Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries
…, MA Mufson, R Riquelme, A Thalme… - The Journal of …, 2000 - academic.oup.com
To define the influence of prognostic factors in patients with community-acquired pneumococcal
bacteremia, a 2-year prospective study was performed in 5 centers in Canada, the …
bacteremia, a 2-year prospective study was performed in 5 centers in Canada, the …
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label …
…, R Mngqibisa, AO Hermida, A Thalme… - The Lancet …, 2021 - thelancet.com
Background Long-acting cabotegravir and rilpivirine administered monthly or every 2 months
might address the challenges associated with daily oral antiretroviral therapy. The ATLAS-…
might address the challenges associated with daily oral antiretroviral therapy. The ATLAS-…
Reduced levels of D-dimer and changes in gut microbiota composition after probiotic intervention in HIV-infected individuals on stable ART
…, P Nowak, FC Nwosu, D Kvale, A Thalme… - JAIDS Journal of …, 2015 - journals.lww.com
Background: Microbial translocation and chronic inflammation may contribute to non-AIDS
morbidity in patients with HIV. This study assessed the impact of probiotic intervention on …
morbidity in patients with HIV. This study assessed the impact of probiotic intervention on …
Swedish guidelines for diagnosis and treatment of infective endocarditis
…, H Rundström, U Snygg-Martin, A Thalme… - … journal of infectious …, 2007 - Taylor & Francis
… Anders Thalme From the Infective Endocarditis Working Group, Swedish Society of …
Westling K, Thalme A, Julander I. Candida albicans tricuspid valve endocarditis in an intravenous …
Westling K, Thalme A, Julander I. Candida albicans tricuspid valve endocarditis in an intravenous …
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a …
…, A Lazzarin, B Rijnders, D Podzamczer, A Thalme… - The lancet HIV, 2017 - thelancet.com
Background Tenofovir alafenamide, a tenofovir prodrug, results in 90% lower tenofovir plasma
concentrations than does tenofovir disproxil fumarate, thereby minimising bone and renal …
concentrations than does tenofovir disproxil fumarate, thereby minimising bone and renal …
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a …
…, G Richmond, G Rizzardini, A Thalme… - Clinical Infectious …, 2023 - academic.oup.com
Background Cabotegravir (CAB) + rilpivirine (RPV) dosed intramuscularly monthly or every
2 months is a complete, long-acting (LA) regimen for the maintenance of HIV-1 virologic …
2 months is a complete, long-acting (LA) regimen for the maintenance of HIV-1 virologic …
[HTML][HTML] Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine …
…, IS Gil, A Blaxhult, L Flamholc, M Gisslén, A Thalme… - Antiviral research, 2019 - Elsevier
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg
was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, …
was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, …
[HTML][HTML] Low mortality but increasing incidence of Staphylococcus aureus endocarditis in people who inject drugs: experience from a Swedish referral hospital
H Asgeirsson, A Thalme, O Weiland - Medicine, 2016 - journals.lww.com
Staphylococcus aureus is a leading cause of infective endocarditis in people who inject
drugs (PWID). The management of S aureus endocarditis (SAE) in PWID can be problematic. …
drugs (PWID). The management of S aureus endocarditis (SAE) in PWID can be problematic. …
